Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samra Turajlic

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
European Urology Open Science|January 15, 2026
Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy TrialsLeo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.
Nature Machine Intelligence|May 28, 2026
Immunotherapy drug target identification using machine learning and patient-derived tumour explant validationMarcellus Augustine, Nuno Rocha Nene, Hongchang Fu, et al.
Histopathology|May 21, 2022
WHO 2022 landscape of papillary and chromophobe renal cell carcinomaJoão Lobo, Riuko Ohashi, Mahul B Amin, et al.
Journal of Hepatology|February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitisCathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Nature|December 10, 2025
Somatic evolution following cancer treatment in normal tissueOriol Pich, Sophia Ward, Andrew Rowan, et al.
Journal for Immunotherapy of Cancer|July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximabJames L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Cell Reports. Medicine|February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trialJames Larkin, Richard Marais, Nuria Porta, et al.
Nature Communications|May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trialRebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.
Nature Ecology & Evolution|May 18, 2021
Selection of metastasis competent subclones in the tumour interiorYue Zhao, Xiao Fu, Jose I Lopez, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
European Urology Open Science|January 15, 2026
Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy TrialsLeo Bickley, Elisabeth E Fransen van de Putte, Luna van den Brink, et al.
Nature Machine Intelligence|May 28, 2026
Immunotherapy drug target identification using machine learning and patient-derived tumour explant validationMarcellus Augustine, Nuno Rocha Nene, Hongchang Fu, et al.
Histopathology|May 21, 2022
WHO 2022 landscape of papillary and chromophobe renal cell carcinomaJoão Lobo, Riuko Ohashi, Mahul B Amin, et al.
Journal of Hepatology|February 25, 2021
Activation and transcriptional profile of monocytes and CD8<sup>+</sup> T cells are altered in checkpoint inhibitor-related hepatitisCathrin L C Gudd, Lewis Au, Evangelos Triantafyllou, et al.
Nature Communications|August 1, 2020
Escape from nonsense-mediated decay associates with anti-tumor immunogenicityKevin Litchfield, James L Reading, Emilia L Lim, et al.
Nature|December 10, 2025
Somatic evolution following cancer treatment in normal tissueOriol Pich, Sophia Ward, Andrew Rowan, et al.
Journal for Immunotherapy of Cancer|July 8, 2021
Clinical outcomes of patients with corticosteroid refractory immune checkpoint inhibitor-induced enterocolitis treated with infliximabJames L Alexander, Hajir Ibraheim, Bhavisha Sheth, et al.
Cell Reports. Medicine|February 28, 2024
Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trialJames Larkin, Richard Marais, Nuria Porta, et al.
Nature Communications|May 21, 2026
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trialRebecca J Lee, Dominic G Rothwell, Nigel Smith, et al.
Nature Ecology & Evolution|May 18, 2021
Selection of metastasis competent subclones in the tumour interiorYue Zhao, Xiao Fu, Jose I Lopez, et al.
Pageof 13